EL. Neoplastic and nonneoplastic complications of solid organ transplantation in patients with preexisting monoclonal gammopathy of undetermined significance.
than 50 yr and 5% of those over 70 yr of age (1) . This disorder is defined by the presence of a serum monoclonal protein at a concentration <3 g/dL, a bone marrow examination with <10% clonal plasma cells (if performed), and the absence of end-organ damage (anemia, hypercalcemia, lytic bone lesions, renal insufficiency, and hyperviscosity) related to the monoclonal protein. Recent studies have shown that PCM is almost always preceded by a plasma cell disorder, most commonly MGUS (2) , and the rate of progression from MGUS to PCM in the general population is predicted to be roughly 1% per year (3) . MGUS also increases the risk of developing PCM approximately 25-fold (4) . In addition, MGUS has been shown to increase the risk of other complications, including infection, venous thromboembolism (VTE), and skeletal-related events (SRE) such as osteoporosis and fracture (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) .
Long-term data regarding patients affected by preexisting MGUS who undergo solid organ transplant are scarce. Solid organ transplant requires long-term use of immunosuppression post-engraftment, which is associated with many risks overlapping those described above, including hematologic malignancies and post-transplant lymphoproliferative disease (PTLD), opportunistic infections, SRE, and VTE. MGUS-affected patients usually are not excluded from transplantation; however, data on long-term outcomes are lacking and limited to single institution studies with relatively small patient numbers (15) (16) (17) . We hypothesized that patients with the precancerous condition, MGUS, are at heightened risk for these post-transplant complications.
Methods
We utilized the 2005-2011 California State Inpatient Database (SID), State Emergency Department Database (SEDD), and State Ambulatory Surgery Database (SASD). These databases are part of the Healthcare Cost and Utilization Project (HCUP), sponsored by the Department of Health and Human Services, Agency for Healthcare Research and Quality. These databases include data from patients discharged from all non-federally funded community hospitals in California, including both not-for-profit and investor-owned hospitals, as well as hospitals run by the state and local governments. Federally run hospitals such as those run by Veterans Affairs or the Indian Health Service are not included, none of which are transplant centers in California. The California HCUP databases include a synthetic patient identifier that can be used to track individuals' utilization of care over the study period and across the emergency department, inpatient hospital, and ambulatory surgery settings. The SID includes over 100 variables including principal and secondary diagnoses and procedures, admission and discharge status, patient demographics characteristics (e.g., sex, age, and race), expected payment source, total charges, length of stay, and hospital characteristics (e.g., location, teaching status, and bed size). A complete list of variables is available in the SID data documentation online (18) . This study was reviewed and approved by the Institutional Review Board (IRB protocol #EM-14-30).
The study population includes patients undergoing solid organ transplant as defined by ICD-9-CM procedure codes (Table S1 ). The main exposure of interest was MGUS, defined using ICD-9-CM diagnosis code 273.1. We searched patient records with diagnosis codes indicating MGUS on the same day or prior to solid organ transplant surgery. The primary outcomes of interest were morbidity and complications as defined by ICD-9-CM diagnosis codes in patient records after solid organ allograft. The outcomes of major interest were PCM, lymphoma, PTLD, opportunistic infection, VTE, and SRE. Infections included bacteremia, viremia, urinary tract infection, Clostridium difficile-associated diarrhea, endocarditis, pneumonia, influenza, and osteomyelitis. As a secondary analysis, we sought to investigate the association of solid organ transplant and poor outcomes among people that had MGUS. Here, the study population included any person with a diagnosis code of MGUS during the study period. The main effect was solid organ transplant occurring on the same date or after the first diagnosis of MGUS.
We conducted a descriptive analysis for all variables in our study. Comparisons between affected and non-affected subjects, MGUS(+) and MGUS (À), respectively, were made using Fisher's exact test for categorical variables and Student's t-test for continuous variables. To protect patient confidentiality, the data use agreement from HCUP required that cells with nonzero counts less than 11 cannot be reported. Therefore, in some cases, we report the data as "≤10," rather than provide the exact cell count.
We used modified Poisson regression to model complications in MGUS(+) vs. MGUS(À) transplant patients to produce risk ratios with robust confidence intervals (19) . To adjust for patient demographics, insurance status, and comorbidities, we included a propensity score as a covariate in the Poisson regression models (20) . The propensity score is defined as the predicted probability of having MGUS conditional on each patient's baseline characteristics (21) . We calculated the propensity score using logistic regression with MGUS as the outcome and patient age, race, sex, count of all Elixhauser comorbidities, insurance, and year of transplant as the covariates. The Elixhauser comorbidity measure includes 30 comorbid conditions defined through secondary ICD-9-CM codes (22) . We also included specific comorbid conditions in the propensity score model if the frequency was greater than five cases in each group. The conditions included were hypertension, diabetes, hypothyroidism, anemia deficiency, electrolyte disorders, renal failure, and liver disease. Models were not fit for PTLD and lymphoma as no patients in the MGUS+ group experienced these outcomes. All of the above analysis was repeated in the MGUS population comparing solid organ transplant (+) vs. solid organ transplant (À). All analyses were conducted on SAS version 9.3 for Unix (SAS Institute, Cary, NC, USA).
Results
Of the 24 358 669 patients in the California State Inpatient, Emergency, and Ambulatory Database from 2005 to 2011, we identified 22 062 solid organ transplant patients. Of these patients, 72 were found to be MGUS(+) prior to solid organ transplant. MGUS was not documented in the remaining 21 990 transplant patients prior to solid organ transplant. Demographic characteristics of solid organ transplant patients are shown in Table 1 . Median age for the MGUS(+) group was somewhat older (61.5 yr vs. 51 yr for the MGUS (À) group, p < 0.001). MGUS(+) solid organ transplant patients had significantly fewer comorbidities than MGUS(À) patients. As there were a number of demographic differences between the groups, propensity score adjusted risk ratios were utilized for further analysis. Table 2 shows the outcomes of interest for solid organ transplant recipients according to MGUS status. There were ≤10 cases of PCM reported in the MGUS(+) group and 37 in the MGUS(À) group. Among solid organ transplant patients, those MGUS(+) patients had a nearly 20-fold higher risk of developing PCM compared to MGUS(À) ( Table 3) , with a propensity score adjusted risk ratio of 19.46 (95% CI 7.05, 53.73). While there were no cases of PTLD or lymphoma in the MGUS(+) group, there were 161 and 193 cases, respectively, in the MGUS(À) group.
For the 72 patients in the MGUS(+) group, we identified a significantly higher incidence of several complications compared to the MGUS(À) group.
Pulmonary embolism, VTEs, SREs, bacteremia, urinary tract infection, C. difficile infection, and pneumonia were found to occur more frequently in While risk for complications or in-hospital death seemed higher for MGUS(+) solid organ transplant recipients, these data did not address the risk for similar MGUS(+) patients without transplant. First, we sought to determine the risk for these outcomes among all MGUS(+) patients with and without solid organ transplant. Utilizing propensity score adjustment, we next sought to determine the risk for these outcomes in MGUS(+) patients according to transplant status. Among MGUS(+) patients, there were ≤10 cases of PCM in those receiving solid organ transplant vs. 1631 for those without transplant (Table 4 ). In fact, PCM risk was decreased with solid organ transplant, with a propensity-adjusted risk ratio of 0.34 (95% CI 0.13, 0.88) for progression of MGUS to PCM. There were no reported PTLD or lymphoma cases in the transplanted MGUS(+) patients, although sample size was somewhat small. There were increased infectious and VTE events in the transplant group, with propensity score adjusted risk ratios of 1.44 (95% CI 1.23, 1.70) and 2.33 (95% CI 1.58, 3.44), respectively (Tables 4 and 5 ). SRE risk was not significantly different once adjusted for propensity score. Unadjusted in-hospital deaths were not significantly different for MGUS(+) patients with solid organ transplants, although significance was uncovered once the cohort was adjusted by propensity score, with an adjusted risk ratio of 1.47 (95% CI 1.09, 1.98) for those MGUS patients with an allograft.
Discussion
Solid organ transplant recipients require long-term immunosuppression post-transplant that may lead to significant complications. We undertook this analysis of HCUP component databases to ascertain whether solid organ transplant recipients affected by a common disorder, MGUS, would be at heightened risk for serious complications that are shared by patients undergoing transplant immunosuppression and by patients with MGUS. Unlike the National Inpatient Sample, the California SID has the advantage of capturing data for a given patient at every California hospital, rather than just the data captured and submitted by the transplant center to the Organ Procurement and Transplantation Network (OPTN), and additionally contains diagnoses and procedures that are unavailable to the OPTN-based sources (23) . While those patients with preexisting MGUS experienced greater overall risks after solid organ transplant, the degree of increased risk suggests that these patients should not be excluded from solid organ transplant options.
Overall PTLD risk for solid organ transplant patients varies by organ-type and immunosuppression protocol. The risk is typically cited to be about 0.4% at one yr for kidney transplant patients (24) , but does not appear to be of high concern in this particular cohort of patients, with PTLD found in only 0.7% of the MGUS(À) patients and none of the MGUS(+) patients. On the other hand, compared to solid organ transplant patients without preexisting MGUS, our data demonstrated that solid organ transplant patients with preexisting MGUS had a significantly higher risk of VTE, SRE, and a variety of infections, including bacteremias, urinary tract infections, C. difficile-associated diarrhea, and infectious pneumonia.
Consistent with other patient populations, we report that solid organ transplant patients with preexisting MGUS are also more likely to develop PCM than those without preexisting MGUS; however, this risk is similar to-or perhaps even lower than-that historically attributed to MGUS in patients who have not undergone transplant. Literature addressing PCM in MGUS patients following solid organ transplant is scarce and conflicting. Safadi et al. (25) reported four of seven multiple myeloma patients with kidney transplants demonstrated preexisting MGUS. In a retrospective review of 1593 solid organ transplant patients, Jimenez-Zipeda et al. (26) reported that none of 34 patients with preexisting MGUS had progression to PCM, amyloid, or lymphoma, and they noted no association between preexisting MGUS and PTLD. In a slightly larger retrospective review of 3518 kidney transplant patients that included 23 patients with preexisting MGUS, four (17.4%) patients developed a hematologic malignancy (two smoldering PCM and two PTLD) (17) . Another small case series in which five transplant patients with preexisting MGUS were followed showed two patients developed smoldering PCM after transplant (27) , with other small studies reporting similar findings (15, 28) . In contrast, we found a somewhat reduced risk for PCM for patients with preexisting MGUS and solid organ transplant. Previous studies tended to be single center and often included patients who developed MGUS post-transplant. Interestingly, in a study of US veterans, MGUS patients with immune-mediated conditions, including autoimmunity, inflammatory disorders, and certain infectious disorders, were found to have increased risk of MGUS progression to PCM (29) . It is certainly possible that solid organ transplant-related immunosuppression alters the likelihood of MGUS progression to PCM.
This study has limitations. There are inherent shortcomings in large retrospective database studies, including inconsistencies inpatient followup, reporting, and coding practices. As the databases relied upon hospitalization or admission to an ambulatory surgery facility or emergency department for entry, subjects receiving care outside of these settings are not represented. Use of other large observational databases, however, suggests that many of the observations are consistent with randomized clinical trials and expert opinion (30, 31) . In addition, as MGUS is present in about 3% of people greater than age 50 yr (1), it is almost certainly underrepresented in this database. Outcomes of MGUS are variable, and a risk stratification system has been developed to predict the risk of progression from MGUS to PCM based on the amount of monoclonal protein, immunoglobulin type, and the serum free light chain ratio (32) . Unfortunately, these databases lack the data granularity to stratify patients based on such differentiation. Similarly, while diagnostic criteria for monoclonal gammopathy of renal significance have been proposed in 2012 (33), the date range from the database we utilized was prior to this proposed term and, in addition, that diagnostic terminology does not have an ICD-9 code independent from the MGUS code (34, 35) . Similarly, the database does not include information on induction and maintenance immunosuppression use, which given the variability in practice and potential modifications in MGUS patients, could impact outcomes. Furthermore, despite the large sample size, the number of transplanted patients with MGUS and event rates was relatively low, thereby limiting statistical power. Sample size also prevented meaningful analysis of organ-specific outcomes-which is pertinent for kidney transplantation, as MGUS is more common in this population. While we adjusted by propensity score to accommodate different levels of comorbidity to minimize selection bias, we can only control for known confounders that we could measure in our data. Further, the small number of cases in the MGUS group prevented us from direct adjustment of particular comorbidities, which may better control for patient differences. Finally, meaningful post-transplant survival analysis is not feasible with this dataset, as in-hospital mortality is biased toward patients requiring more frequent admission.
In conclusion, patients with preexisting MGUS who undergo solid organ transplantation have higher risks compared to MGUS-unaffected patients for developing complications such as PCM, VTE, SRE, and opportunistic infections. However, solid organ transplant in patients with preexisting MGUS does not appear to further increase the risk of progression to PCM in patients with solid organ transplant, nor do PTLD and lymphoma risks seem to increase. In contrast, solid organ transplant patients with preexisting MGUS are at higher risk for VTE, SRE, and infection, suggesting that closer monitoring for such events is warranted. While MGUS is a risk factor for future PCM, it should not preclude solid organ transplantation.
